Merck’S Remigromig, A Tri-Specific Agonist Of The Wingless-Related Integration Site Pathway, Met Primary Endpoint In The Pivotal Phase 2B/3 Brunello Study Of Adults With Diabetic Macular Edema
Merck & Co Inc NYSE:MRK
Story updates
10:50:43 AM UTC
SquawkNews
MRK - Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema